MedPath

The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

Active, not recruiting
Conditions
Biliary Tract Cancer (BTC)
Registration Number
NCT05036486
Lead Sponsor
National Health Research Institutes, Taiwan
Brief Summary

Recent progress in comprehensive genomic profiling for advanced BTC has helped to clarify tumorigenesis and facilitate the coming era of precision medicine. To further elucidate the underlying molecular genomic aberrations, as well as the clinical demographics and therapeutic outcomes, it is necessary to have a national, multi-centers and population-focused research project to collect data completely. Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis in a platform of data storage and sharing. The purpose of the precision medicine project is to establish tumor molecular profiling of BTC populations in Taiwan, to facilitate patients to have corresponding potential targeted therapeutics and suitable clinical trials.

Detailed Description

Biliary tract cancer (BTC) compromises a heterogenous group of tumors with poor prognoses. Curative surgery remains the first choice for localized disease; however, most BTC patients had unresectable or metastatic disease. The gold standard therapy for these patients is chemotherapy with gemcitabine and cisplatin. There are no consensus guidelines for standard treatment in a second-line setting, although the data of the ABC-06 trial showed a slight survival benefit from oxaliplatin and 5-fluorouracil combination chemotherapy.

Recent progress in comprehensive genomic profiling for advanced BTC has helped to clarify tumorigenesis and facilitate the coming era of precision medicine. To further elucidate the underlying molecular genomic aberrations, as well as the clinical demographics and therapeutic outcomes, it is necessary to have a national, multi-centers and population-focused research project to collect data completely. Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis in a platform of data storage and sharing. The purpose of the precision medicine project is to establish tumor molecular profiling of BTC populations in Taiwan, to facilitate patients to have corresponding potential targeted therapeutics and suitable clinical trials.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
480
Inclusion Criteria
  1. Ages 20 and above.
  2. Pathological reported showed adenocarcinoma or adenosquamous carcinoma for patients with BTC (include IHCC, EHCC, GBC or AVC) or hepatocholangiocarcinoma as locally advanced or metastatic status.
  3. Willingness to provide the residual biopsy/operative slides.
  4. Life expectancy more than 3 months.
  5. Patients fully understand the protocol with the willingness to have regular follow-up.
  6. Patients are ready to have 1st systemic treatment or under 1st line therapy
  7. Total bilirubin ≦5 mg/dL, and ECOG≦2
Exclusion Criteria
  1. Inability to cooperate by providing a complete medical history.
  2. No available tumor tissues for genetic testing.
  3. Undesirable compliance.
  4. Other malignancy within the past 1 years except adequately treated basal or squamous cell skin cancer or cervical cancer in situ.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To perform large-scale NGS analysis for specific populations5 years

To create a map containing important genetic characteristics

To enroll 400 patients who fit the criteria of this study in the enrolled period5 years

To enroll 400 patients who fit the criteria of this study in the enrolled period

Secondary Outcome Measures
NameTimeMethod
To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer with the genetic profile in Taiwan.5 years

To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer patients

Collect clinical data of Biliary tract cancer patients5 years

Collect clinical data of Biliary tract cancer patients

Trial Locations

Locations (13)

Chang Gung Memorial Hospital, Chiayi

🇨🇳

Chiayi City, Taiwan

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital,

🇨🇳

Kaohsiung, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center

🇨🇳

Taipei, Taiwan

MacKay Memorial Hospital

🇨🇳

Taipei, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Taipei Medical University-Shuang Ho Hospital

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Scroll for more (3 remaining)
Chang Gung Memorial Hospital, Chiayi
🇨🇳Chiayi City, Taiwan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.